RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Batten Disease: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Functional ultrasound imaging reveals early pathway-specific reorganization of central visual circuits in a mouse model of Batten disease.
Yin Fanchao et al., Neurobiology of disease (15 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42632523/
- 2.
CLN6 is a glycerophosphoglycerol epimerase in bis(monoacylglycero)phosphate biosynthesis
Pradeep Kumar Sheokand et al., bioRxiv (Cold Spring Harbor Laboratory) (9 October 2026)
https://doi.org/10.64898/2026.10.07.757350
- 3.
The Batten disease gene product CLN6 is a glycerophosphoglycerol epimerase that establishes S,S -BMP stereochemistry
Zhijun Zhu et al., bioRxiv (Cold Spring Harbor Laboratory) (9 October 2026)
https://doi.org/10.64898/2026.10.07.757477
- 4.
The calcium channel blocker diltiazem ameliorates parthanatos in juvenile neuronal ceroid lipofuscinosis.
Kim Hyungkuen et al., Journal of molecular medicine (Berlin, Germany) (7 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42841989/
- 5.
Biofluid Proteomic Biomarker Discovery in a Large Animal Model of CLN2 Neuronal Ceroid Lipofuscinosis.
Morgan-Jack Brandie R et al., Biology (2 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42883434/
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Batten Disease
Batten disease (neuronal ceroid lipofuscinosis) is a group of rare and fatal genetic neurological disorders that cause progressive deterioration of vision, seizures, and cognitive and motor decline, often beginning in childhood. The first approved enzyme replacement therapy (cerliponase alfa) targets CLN2 disease and has slowed progression.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
CLN3 disease, or juvenile Batten disease, is a neurodegenerative lysosomal storage disorder in which visual impairment is typically the earliest clinical manifestation. Although retinal pathology has been extensively studied, functional alterations within central visual pathways remain poorly understood. Here, we used functional ultrasound (fUS) imaging to characterize visually evoked activity across central visual circuits in young Cln3 knockout (Cln3-/-) mice before the onset of severe retinal degeneration. Visually evoked hemodynamic responses were quantified in regions spanning the geniculostriate and extrageniculate visual pathways, including cortical, thalamic, and midbrain regions. Regional pathological burden was assessed by immunohistochemical quantification of subunit c of mitochondrial ATP synthase (SCMAS), a hallmark pathological marker of CLN3 disease. Young Cln3-/- mice exhibited pathway-specific reorganization of visually evoked responses, with enhanced fUS activation in the extrageniculate pathway, including the midbrain, posterior thalamus, and anterior secondary visual cortex, whereas activation in the geniculostriate pathway was reduced in the anterior thalamus and preserved in the visual cortex relative to wild-type controls. SCMAS accumulation was increased across all examined visual regions but was greater in geniculostriate than extrageniculate regions, indicating differential regional vulnerability. Together, these findings identify early pathway-specific reorganization of central visual circuits before overt neurodegeneration and establish fUS imaging, combined with quantitative histopathology, as a promising approach for early detection and longitudinal monitoring of central nervous system dysfunction in CLN3 disease and related lysosomal storage disorders.
Common Questions
What is Batten Disease?
Batten disease (neuronal ceroid lipofuscinosis) is a group of rare and fatal genetic neurological disorders that cause progressive deterioration of vision, seizures, and cognitive and motor decline, often beginning in childhood. The first approved enzyme replacement therapy (cerliponase alfa) targets CLN2 disease and has slowed progression.
How many clinical trials are available for Batten Disease?
RareWays currently indexes 21 clinical trials for Batten Disease, of which 2 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Batten Disease come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Batten Disease.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.